Tag
A four-year post hoc analysis of the TOPAZ-1 trial confirms that durvalumab combined with gemcitabine and cisplatin offers a long-term survival benefit with manageable safety as first-line treatment for advanced biliary tract cancer.
A randomized trial found that maintaining high intraoperative urine output (≥3 ml·kg−1·h−1 or ≥200 ml·h−1) during cytoreductive surgery and cisplatin‑based HIPEC reduced 7‑day postoperative AKI from 39.3% to 21.4% and lowered major 30‑day c
A multicenter retrospective cohort shows weekly low‑dose cisplatin markedly lowers ototoxicity compared with standard high‑dose every‑3‑week cisplatin in CRT for head and neck squamous cell carcinoma, with similar two‑year survival.
The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.
A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.
The NuTide:121 phase III trial compared NUC-1031/cisplatin to gemcitabine/cisplatin in treatment-naïve advanced biliary tract cancer but was terminated early due to lack of survival benefit and increased liver toxicity with NUC-1031.
Cisplatin chemotherapy is associated with predictable kidney function decline, with pre-treatment eGFR effectively forecasting chronic kidney disease risk post-treatment. Simple models outperform complex approaches, offering practical clini
